Your session is about to expire
← Back to Search
Semaglutide for Cognitive Impairment in Depression
Study Summary
This trial will test whether semaglutide can improve cognitive function in people with MDD.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 104 Patients • NCT04189848Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have used diabetes medication or insulin in the last 4 weeks.I have a history of neurological disorders or illnesses that could affect my thinking.My BMI is 25 or higher, indicating I am overweight.I have been diagnosed with Alzheimer's, Mild Cognitive Impairment, or another form of dementia.I am between 18 and 60 years old and have been diagnosed with major depression.I am experiencing a severe episode of depression.I cannot take semaglutide due to allergies, liver or severe kidney problems, or a family history of certain cancers.I have been diagnosed with OCD, PTSD in the last year, or borderline personality disorder.I have had pancreatitis or pancreatic cancer.I have had diabetic eye disease in the past.You have thoughts of hurting yourself or have been identified as being at risk for suicide by a doctor or mental health professional.
- Group 1: Semaglutide
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are participants being onboarded for this research trial?
"The clinical trial is actively searching for participants, with the initial posting occurring on October 6th 2021 and a subsequent update made on February 11th 2022. This can be verified through data hosted on clinicaltrials.gov."
Are there any additional research initiatives exploring the efficacy of Semaglutide?
"As of now, 58 trials for Semaglutide are live. A total of 27 clinical studies are in the final phase before approval. Though the majority of research is conducted in Loma Linda, California, a staggering 3907 sites globally have initiated testing on this medication."
What safeguards are in place to ensure patient safety when taking Semaglutide?
"Due to the lack of clinical data that verifies semaglutide's efficacy, it was assigned a score of 2 in regards to safety."
Is this medical experiment the inaugural trial of its type?
"As of present, Novo Nordisk A/S sponsors 58 active Semaglutide studies across 772 cities and 55 countries. To date, 18433 trials have been initiated since the initial 2018 trial involving 1387 participants that reached Phase 4 in its drug approval process."
Is the age of 75+ a criterion for enrollment in this trial?
"According to the inclusion criteria, only individuals aged 18-60 can participate in this research. Patients under 18 and those over 65 have been enrolled into 223 and 1529 studies respectively."
What are the eligibility criteria for participation in this clinical trial?
"This clinical trial is accepting applications from individuals aged 18-60 who are experiencing symptoms of melancholia. A total of 60 people will participate in the study."
What is the cap on participant numbers for this clinical trial?
"Confirmed. The trial details available on clinicaltrials.gov reveal that this medical experiment, which was first published on October 6th 2021, is actively recruiting participants. Approximately 60 patients will be taken in by a single site and enrolled in the study."
Share this study with friends
Copy Link
Messenger